Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 390
- Registration Number
- NCT06123754
- Locations
- 🇨🇳
Tianjin cancer hospital, Tianjing, Tianjin, China
Phase I Trial of Envafolimab for Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT05849311
- Locations
- 🇨🇳
Beijing Gaobo Boren Hosipital, Beijing, Beijing, China
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT05112991
- Locations
- 🇨🇳
Chongqing University Three Gorges Hospital, Chongqing, Chongqing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 170
- Registration Number
- NCT05024214
- Locations
- 🇨🇳
THE First Hospital of Jilin University, Changchun, Jilin, China
🇨🇳Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
- Conditions
- Interventions
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT04910386
ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT04891198
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
KN035 for dMMR/MSI-H Advanced Solid Tumors
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT03667170
- Locations
- 🇨🇳
Peking University Cancer Hospital, Peking University, Beijing, Beijing, China
Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC
- Conditions
- Interventions
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 480
- Registration Number
- NCT03478488
- Locations
- 🇨🇳
The Chinese people's liberation army (PLA) 81hospital, Nanjing, Jiangsu, China
A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT03248843
- Locations
- 🇯🇵
St. Marianna University School of Medicine Hospital, Kawasaki, Japan
🇯🇵National Cancer Center Hospital, Tokyo, Japan
Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 287
- Registration Number
- NCT03101488
- Locations
- 🇨🇳
Zhongshan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
🇨🇳First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China